身体成分参数对纳武利尤单抗严重毒性的影响
该前瞻性研究纳入92例接受纳武利尤单抗治疗的患者(肺癌占72%),探讨CT评估的肌肉量、第14天纳武利尤单抗谷浓度与免疫相关急性限制性毒性(irALT)的关系。多因素分析显示低白蛋白血症与第14天低谷浓度独立相关,超重/肥胖与高谷浓度独立相关;肌肉减少症患者发生irALT风险显著增加(OR=3.84,95%CI 1.02-14.46,p=0.047),毒性发生与第14天血药谷浓度无关。
要点
- 肌肉减少症与纳武利尤单抗严重免疫相关毒性风险独立相关,OR=3.84(95%CI 1.02-14.46,p=0.047)。
- 低白蛋白血症(<35 g/L)与第14天低纳武利尤单抗谷浓度独立相关。
- 第14天纳武利尤单抗血浆谷浓度与irALT发生无显著关联。
核心结论
- 肌肉减少症可能预测真实世界中纳武利尤单抗的严重免疫相关毒性。
研究设计与样本
- 前瞻性队列研究,2015年6月至2017年1月连续纳入本机构接受纳武利尤单抗治疗的患者92例,其中肺癌占72%。
主要发现
- 最常见irALT为呼吸系统疾病(6.5%)和胃肠道疾病(4.3%)。
- 肌肉减少症患者发生irALT风险显著增加(OR=3.84;95%CI=1.02-14.46,p=0.047)。
- 第14天纳武利尤单抗中位血浆谷浓度为15.4 μg/mL(四分位距=11.8-21.0)。
- 多因素分析中,低白蛋白血症(<35 g/L)与第14天低纳武利尤单抗谷浓度独立相关(OR=0.09;95%CI=0.01-0.59,p=0.01),超重/肥胖与高谷浓度独立相关(OR=5.94;95%CI=1.25-28.29,p=0.03)。
临床怎么用
- 在纳武利尤单抗治疗前评估身体成分(如CT肌肉量)有助于识别严重免疫相关毒性高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The occurrence of severe, acute limiting toxicity in patients receiving anti-programmed cell death receptor-1 monoclonal antibodies, such as nivolumab, is largely unpredictable. Sarcopenia was found to be associated with anti-cytotoxic T-lymphocyte-associated protein 4 acute toxicity. We explore the clinical and pharmacological parameters influencing nivolumab toxicity, including body composition. METHODS: From June 2015 to January 2017, all consecutive patients treated with nivolumab in our institution were prospectively included. We studied the relationship between muscle mass assessed by computed tomography, nivolumab trough level (Cmin) at day 14 assessed using the enzyme-linked immunosorbent assay method, and the occurrence of immune grade III or IV toxicity or any toxicity leading to treatment discontinuation (immune-related acute limiting toxicity [irALT]). RESULTS: In our population (n = 92) with a majority of lung cancer (72%), forty-five (51.7%) patients were sarcopenic. The median plasma nivolumab Cmin at day 14 was 15.4 μg/mL (interquartile range = 11.8-21.0). In multivariate analysis, hypoalbuminaemia (<35 g/L) was independently associated with low nivolumab Cmin on day 14 (odds ratio [OR] = 0.09; 95% confidence interval [CI] = 0.01-0.59, p = 0.01) and overweight/obesity with high nivolumab Cmin on day 14 (OR = 5.94; 95% CI = 1.25-28.29, p = 0.03). We observed 22 irALTs in 19 patients (21%). The most frequent irALT was respiratory (6.5%) disorders and gastrointestinal (4.3%) disorders. Patients with sarcopenia were at significantly increased risk of experiencing an irALT (OR = 3.84; 95% CI = 1.02-14.46, p = 0.047). No association was found between toxicity and nivolumab plasma Cmin at day 14. CONCLUSIONS: Our results highlight the importance of assessing body composition and suggest that sarcopenia could predict severe immune-related toxicity of nivolumab in real life.
引用
- Hirsch L, Bellesoeur A, Boudou-Rouquette P, et al. The impact of body composition parameters on severe toxicity of nivolumab. Eur J Cancer. 2019. PMID: 31794927. doi:10.1016/j.ejca.2019.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。